51
|
The emerging use of in vivo optical imaging in the study of neurodegenerative diseases. BIOMED RESEARCH INTERNATIONAL 2014; 2014:401306. [PMID: 25147799 PMCID: PMC4132409 DOI: 10.1155/2014/401306] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/09/2014] [Revised: 06/25/2014] [Accepted: 06/26/2014] [Indexed: 12/12/2022]
Abstract
The detection and subsequent quantification of photons emitted from living tissues, using highly sensitive charged-couple device (CCD) cameras, have enabled investigators to noninvasively examine the intricate dynamics of molecular reactions in wide assortment of experimental animals under basal and pathophysiological conditions. Nevertheless, extrapolation of this in vivo optical imaging technology to the study of the mammalian brain and related neurodegenerative conditions is still in its infancy. In this review, we introduce the reader to the emerging use of in vivo optical imaging in the study of neurodegenerative diseases. We highlight the current instrumentation that is available and reporter molecules (fluorescent and bioluminescent) that are commonly used. Moreover, we examine how in vivo optical imaging using transgenic reporter mice has provided new insights into Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Prion disease, and neuronal damage arising from excitotoxicity and inflammation. Furthermore, we also touch upon studies that have utilized these technologies for the development of therapeutic strategies for neurodegenerative conditions that afflict humans.
Collapse
|
52
|
Naumova AV, Balu N, Yarnykh VL, Reinecke H, Murry CE, Yuan C. Magnetic Resonance Imaging Tracking of Graft Survival in the Infarcted Heart: Iron Oxide Particles Versus Ferritin Overexpression Approach. J Cardiovasc Pharmacol Ther 2014; 19:358-367. [PMID: 24685664 DOI: 10.1177/1074248414525999] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The main objective of cell therapy is the regeneration of damaged tissues. To distinguish graft from host tissue by magnetic resonance imaging (MRI), a paramagnetic label must be introduced to cells prior to transplantation. The paramagnetic label can be either exogenous iron oxide nanoparticles or a genetic overexpression of ferritin, an endogenous iron storage protein. The purpose of this work was to compare the efficacy of these 2 methods for MRI evaluation of engrafted cell survival in the infarcted mouse heart. Mouse skeletal myoblasts were labeled either by cocultivation with iron oxide particles or by engineering them to overexpress ferritin. Along with live cell transplantation, 2 other groups of mice were injected with dead-labeled cells. Both particle-labeled and ferritin-tagged grafts were detected as areas of MRI signal hypointensity in the left ventricle of the mouse heart using T2*-weighted sequences, although the signal attenuation decreased with ferritin tagging. Importantly, live cells could not be distinguished from dead cells when labeled with iron oxide particles, whereas the ferritin tagging was detected only in live grafts, thereby allowing identification of viable grafts using MRI. Thus, iron oxide particles can provide information about initial cell injection success but cannot assess graft viability. On the other hand, genetically based cell tagging, such as ferritin overexpression, despite having lower signal intensity in comparison with iron oxide particles, is able to identify live transplanted cells.
Collapse
Affiliation(s)
- Anna V Naumova
- Department of Radiology, University of Washington, Seattle, WA, USA Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA
| | - Niranjan Balu
- Department of Radiology, University of Washington, Seattle, WA, USA Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA
| | - Vasily L Yarnykh
- Department of Radiology, University of Washington, Seattle, WA, USA Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA
| | - Hans Reinecke
- Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA Department of Pathology, University of Washington, Seattle, WA, USA
| | - Charles E Murry
- Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA Department of Pathology, University of Washington, Seattle, WA, USA Department of Bioengineering, University of Washington, Seattle, WA, USA Department of Medicine/Cardiology, University of Washington, Seattle, WA, USA
| | - Chun Yuan
- Department of Radiology, University of Washington, Seattle, WA, USA Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA Department of Bioengineering, University of Washington, Seattle, WA, USA
| |
Collapse
|
53
|
Bernau K, Lewis CM, Petelinsek AM, Benink HA, Zimprich CA, Meyerand ME, Suzuki M, Svendsen CN. In vivo tracking of human neural progenitor cells in the rat brain using bioluminescence imaging. J Neurosci Methods 2014; 228:67-78. [PMID: 24675049 DOI: 10.1016/j.jneumeth.2014.03.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Revised: 03/13/2014] [Accepted: 03/14/2014] [Indexed: 01/01/2023]
Abstract
BACKGROUND Stem cell therapies appear promising for treating certain neurodegenerative disorders and molecular imaging methods that track these cells in vivo could answer some key questions regarding their survival and migration. Bioluminescence imaging (BLI), which relies on luciferase expression in these cells, has been used for this purpose due to its high sensitivity. NEW METHOD In this study, we employ BLI to track luciferase-expressing human neural progenitor cells (hNPC(Luc2)) in the rat striatum long-term. RESULTS We show that hNPC(Luc2) are detectable in the rat striatum. Furthermore, we demonstrate that using this tracking method, surviving grafts can be detected in vivo for up to 12 weeks, while those that were rejected do not produce bioluminescence signal. We also demonstrate the ability to discern hNPC(Luc2) contralateral migration. COMPARISON WITH EXISTING METHODS Some of the advantages of BLI compared to other imaging methods used to track progenitor/stem cells include its sensitivity and specificity, low background signal and ability to distinguish surviving grafts from rejected ones over the long term while the blood-brain barrier remains intact. CONCLUSIONS These new findings may be useful in future preclinical applications developing cell-based treatments for neurodegenerative disorders.
Collapse
Affiliation(s)
- Ksenija Bernau
- University of Wisconsin-Madison, 4325a Veterinary Medicine Building, 2015 Linden Dr., Madison, WI 53706, USA.
| | - Christina M Lewis
- University of Wisconsin-Madison, 1005 Wisconsin Institute for Medical Research, 1111 Highland Ave., Madison, WI 53705, USA.
| | - Anna M Petelinsek
- University of Wisconsin-Madison, 4325a Veterinary Medicine Building, 2015 Linden Dr., Madison, WI 53706, USA.
| | - Hélène A Benink
- Promega Corporation, 2800 Woods Hollow Rd., Fitchburg, WI 53711, USA.
| | - Chad A Zimprich
- Promega Corporation, 2800 Woods Hollow Rd., Fitchburg, WI 53711, USA.
| | - M Elizabeth Meyerand
- University of Wisconsin-Madison, 1129 Wisconsin Institute for Medical Research, 1111 Highland Ave., Madison, WI 53705, USA.
| | - Masatoshi Suzuki
- University of Wisconsin-Madison, 4124 Veterinary Medicine Building, 2015 Linden Dr., Madison, WI 53706, USA.
| | - Clive N Svendsen
- University of Wisconsin-Madison, 5009 Wisconsin Institute for Medical Research, 1111 Highland Ave., Madison, WI 53705, USA.
| |
Collapse
|
54
|
Boehm-Sturm P, Aswendt M, Minassian A, Michalk S, Mengler L, Adamczak J, Mezzanotte L, Löwik C, Hoehn M. A multi-modality platform to image stem cell graft survival in the naïve and stroke-damaged mouse brain. Biomaterials 2013; 35:2218-26. [PMID: 24355489 DOI: 10.1016/j.biomaterials.2013.11.085] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2013] [Accepted: 11/27/2013] [Indexed: 02/08/2023]
Abstract
Neural stem cell implantations have been extensively investigated for treatment of brain diseases such as stroke. In order to follow the localization and functional status of cells after implantation noninvasive imaging is essential. Therefore, we developed a comprehensive multi-modality platform for in vivo imaging of graft localization, density, and survival using 19F magnetic resonance imaging in combination with bioluminescence imaging. We quantitatively analyzed cell graft survival over the first 4 weeks after transplantation in both healthy and stroke-damaged mouse brain and correlated our findings of graft vitality with the host innate immune response. The multi-modality imaging platform will help to improve cell therapy also in context other than stroke and to gain indispensable information for clinical translation.
Collapse
Affiliation(s)
- Philipp Boehm-Sturm
- In-Vivo-NMR Laboratory, Max-Planck-Institute for Neurological Research in Cologne, Cologne, Germany
| | - Markus Aswendt
- In-Vivo-NMR Laboratory, Max-Planck-Institute for Neurological Research in Cologne, Cologne, Germany
| | - Anuka Minassian
- In-Vivo-NMR Laboratory, Max-Planck-Institute for Neurological Research in Cologne, Cologne, Germany
| | - Stefanie Michalk
- In-Vivo-NMR Laboratory, Max-Planck-Institute for Neurological Research in Cologne, Cologne, Germany
| | - Luam Mengler
- In-Vivo-NMR Laboratory, Max-Planck-Institute for Neurological Research in Cologne, Cologne, Germany
| | - Joanna Adamczak
- In-Vivo-NMR Laboratory, Max-Planck-Institute for Neurological Research in Cologne, Cologne, Germany
| | - Laura Mezzanotte
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Clemens Löwik
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Mathias Hoehn
- In-Vivo-NMR Laboratory, Max-Planck-Institute for Neurological Research in Cologne, Cologne, Germany; Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
| |
Collapse
|
55
|
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. Proc Natl Acad Sci U S A 2013; 110:20801-6. [PMID: 24297888 DOI: 10.1073/pnas.1312159110] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
ATP-binding cassette (ABC) transporters are a group of transmembrane proteins that maintain chemical homeostasis through efflux of compounds out of organelles and cells. Among other functions, ABC transporters play a key role in protecting the brain parenchyma by efflux of xenobiotics from capillary endothelial cells at the blood-brain barrier (BBB). They also prevent the entry of therapeutic drugs at the BBB, thereby limiting their efficacy. One of the key transporters playing this role is ABCG2. Although other ABC transporters can be studied through various imaging modalities, no specific probe exists for imaging ABCG2 function in vivo. Here we show that D-luciferin, the endogenous substrate of firefly luciferase, is a specific substrate for ABCG2. We hypothesized that ABCG2 function at the BBB could be evaluated by using bioluminescence imaging in transgenic mice expressing firefly luciferase in the brain. Bioluminescence signal in the brain of mice increased with coadministration of the ABCG2 inhibitors Ko143, gefitinib, and nilotinib, but not an ABCB1 inhibitor. This method for imaging ABCG2 function at the BBB will facilitate understanding of the function and pharmacokinetic inhibition of this transporter.
Collapse
|
56
|
Stout D, Berr SS, LeBlanc A, Kalen JD, Osborne D, Price J, Schiffer W, Kuntner C, Wall J. Guidance for Methods Descriptions Used in Preclinical Imaging Papers. Mol Imaging 2013. [DOI: 10.2310/7290.2013.00055] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- David Stout
- From the Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Departments of Radiology and Biomedical Engineering, University of Virginia, Charlottesville, VA; Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN; Small Animal Imaging Program/Laboratory Animal Sciences Program/SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD; Departments of Medicine
| | - Stuart S. Berr
- From the Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Departments of Radiology and Biomedical Engineering, University of Virginia, Charlottesville, VA; Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN; Small Animal Imaging Program/Laboratory Animal Sciences Program/SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD; Departments of Medicine
| | - Amy LeBlanc
- From the Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Departments of Radiology and Biomedical Engineering, University of Virginia, Charlottesville, VA; Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN; Small Animal Imaging Program/Laboratory Animal Sciences Program/SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD; Departments of Medicine
| | - Joseph D. Kalen
- From the Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Departments of Radiology and Biomedical Engineering, University of Virginia, Charlottesville, VA; Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN; Small Animal Imaging Program/Laboratory Animal Sciences Program/SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD; Departments of Medicine
| | - Dustin Osborne
- From the Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Departments of Radiology and Biomedical Engineering, University of Virginia, Charlottesville, VA; Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN; Small Animal Imaging Program/Laboratory Animal Sciences Program/SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD; Departments of Medicine
| | - Julie Price
- From the Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Departments of Radiology and Biomedical Engineering, University of Virginia, Charlottesville, VA; Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN; Small Animal Imaging Program/Laboratory Animal Sciences Program/SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD; Departments of Medicine
| | - Wynne Schiffer
- From the Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Departments of Radiology and Biomedical Engineering, University of Virginia, Charlottesville, VA; Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN; Small Animal Imaging Program/Laboratory Animal Sciences Program/SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD; Departments of Medicine
| | - Claudia Kuntner
- From the Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Departments of Radiology and Biomedical Engineering, University of Virginia, Charlottesville, VA; Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN; Small Animal Imaging Program/Laboratory Animal Sciences Program/SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD; Departments of Medicine
| | - Jonathan Wall
- From the Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Departments of Radiology and Biomedical Engineering, University of Virginia, Charlottesville, VA; Department of Small Animal Clinical Sciences, College of Veterinary Medicine, The University of Tennessee, Knoxville, TN; Small Animal Imaging Program/Laboratory Animal Sciences Program/SAIC-Frederick, Frederick National Laboratory for Cancer Research, Frederick, MD; Departments of Medicine
| |
Collapse
|
57
|
Myburgh E, Coles JA, Ritchie R, Kennedy PGE, McLatchie AP, Rodgers J, Taylor MC, Barrett MP, Brewer JM, Mottram JC. In vivo imaging of trypanosome-brain interactions and development of a rapid screening test for drugs against CNS stage trypanosomiasis. PLoS Negl Trop Dis 2013; 7:e2384. [PMID: 23991236 PMCID: PMC3749981 DOI: 10.1371/journal.pntd.0002384] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2013] [Accepted: 07/13/2013] [Indexed: 11/18/2022] Open
Abstract
HUMAN AFRICAN TRYPANOSOMIASIS (HAT) MANIFESTS IN TWO STAGES OF DISEASE: firstly, haemolymphatic, and secondly, an encephalitic phase involving the central nervous system (CNS). New drugs to treat the second-stage disease are urgently needed, yet testing of novel drug candidates is a slow process because the established animal model relies on detecting parasitemia in the blood as late as 180 days after treatment. To expedite compound screening, we have modified the GVR35 strain of Trypanosoma brucei brucei to express luciferase, and have monitored parasite distribution in infected mice following treatment with trypanocidal compounds using serial, non-invasive, bioluminescence imaging. Parasites were detected in the brains of infected mice following treatment with diminazene, a drug which cures stage 1 but not stage 2 disease. Intravital multi-photon microscopy revealed that trypanosomes enter the brain meninges as early as day 5 post-infection but can be killed by diminazene, whereas those that cross the blood-brain barrier and enter the parenchyma by day 21 survived treatment and later caused bloodstream recrudescence. In contrast, all bioluminescent parasites were permanently eliminated by treatment with melarsoprol and DB829, compounds known to cure stage 2 disease. We show that this use of imaging reduces by two thirds the time taken to assess drug efficacy and provides a dual-modal imaging platform for monitoring trypanosome infection in different areas of the brain.
Collapse
Affiliation(s)
- Elmarie Myburgh
- Wellcome Trust Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Jonathan A. Coles
- Wellcome Trust Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Ryan Ritchie
- Wellcome Trust Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Peter G. E. Kennedy
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Alex P. McLatchie
- Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Jean Rodgers
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Martin C. Taylor
- Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Michael P. Barrett
- Wellcome Trust Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
- * E-mail:
| | - James M. Brewer
- Wellcome Trust Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Jeremy C. Mottram
- Wellcome Trust Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| |
Collapse
|
58
|
Modulation of neural stem/progenitor cell proliferation during experimental Herpes Simplex encephalitis is mediated by differential FGF-2 expression in the adult brain. Neurobiol Dis 2013; 58:144-55. [PMID: 23748078 DOI: 10.1016/j.nbd.2013.05.018] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2012] [Revised: 05/07/2013] [Accepted: 05/22/2013] [Indexed: 11/20/2022] Open
Abstract
Neural stem cells (NSCs) respond to inflammatory cues induced during brain injury and are thought to be involved in recovery from brain damage. Little is known about NSC response during brain infections. The present study evaluated NSC proliferation during Herpes Simplex Virus-1 brain infection. Total numbers of nestin(+) NSCs increased significantly in infected brains at 6 days post infection (p.i.). However, by 15 days p.i. the nestin(+) population decreased significantly below levels observed in uninfected brains and remained depressed through 30 days p.i. This initial increase in NSC population occurred concurrently with increased brain cell proliferation, which peaked at 3 days p.i. On closer examination, we found that while actively proliferating Sox2(+) NSCs increased in number at 6 days p.i., proliferating DCX(+) neuroblasts contributed to the increased response at 3 days p.i. However, overall proliferation decreased steadily from 15 days p.i. to below control levels. To determine the mechanisms involved in altering NSC proliferation, neurotrophin and growth factor expression profiles were assessed. FGF-2 gene expression increased at 5 days p.i. and was robustly down-regulated at 15 days p.i. (>1000-fold), which was further confirmed by increased FGF-2 immunostaining around the lateral ventricles. Furthermore, supplementing infected animals with recombinant FGF-2, at 15 days p.i., significantly increased the number of proliferating brain cells. These findings demonstrate that the temporal changes in NSC proliferation are mediated through the regulation of FGF-2 and that the NSC niche may benefit from supplementation with FGF-2 during HSV-1 brain infection.
Collapse
|